Trial Information

Summary: A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

This clinical study (The HER2+ Research Study) is examining an investigational medication for safety and effectiveness in slowing the progression of HER2-positive metastatic breast cancer when used in combination with Herceptin and docetaxel.

Study inclusion/exclusion criteria

  • At least 18 years old
  • Diagnosed with HER2-positive metastatic breast cancer
  • Eligible for chemotherapy

To learn more about this study, please Visit Our Website where you may also take an online prescreener to see if you may be eligible.

Or contact:

Contact:

Wendy Sabbah
Tower Hematology Oncology Medi
9229 Wilshire Blvd
Beverly Hills, CA 90210
Telephone: (310) 205-5703
Fax: (310) 285-7298
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:45:13 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA